Merlin Receives Investment From Vanderbilt University Chancellor's Investment Fund

Apr 18, 2001, 01:00 ET from Merlin Technologies, Inc.

    BOSTON, April 18 /PRNewswire/ -- Vanderbilt's Chancellor's Investment Fund
 (Nashville) increased Vanderbilt's equity position in Merlin Technologies,
 Inc. (Boston), an early stage pharmaceutical company, through an investment
 package totaling more than one million dollars.  G. Mick Stadler, Managing
 Director of the Vanderbilt Fund, joined Merlin's prestigious Board of
 Directors. Merlin's Directors include Walter Gilbert, PhD, Nobel laureate and
 former founding CEO of Biogen, Barry Eisenstein, former Lilly executive and
 current VP of Science and Technology at the Beth Israel Deaconess Medical
 Center, and Raymond Baddour, PhD, former chemical engineering chair at MIT and
 co-founder and former director of Amgen.
     Merlin also received exclusive worldwide licensure of Vanderbilt
 intellectual property covering the diagnosis and treatment of certain
 bacterial stealth infections.  Stealth infections, especially persistent
 infections by Chlamydia pneumoniae, have been linked to heart disease,
 multiple sclerosis and many other deadly ailments. Vanderbilt researchers
 Charles W. Stratton, MD and William Mitchell, MD, PhD, and Boston biotech
 entrepreneur, Gary Magnant, co-founded Merlin in 1996.
     Merlin's CEO, Chalom Sayada, MD, PhD called the deal "a key milestone for
 the Company. The addition of Vanderbilt's intellectual property to our
 portfolio gives Merlin the most comprehensive pending patent coverage of its
 kind in the world.  The detection and treatment of Chlamydia pneumoniae and
 the chronic diseases induced by this organism are broadly covered, and will
 enable strong strategic partnerships with large pharmaceutical companies."
     Mick Stadler concurs: "We are pleased to back this exciting early stage
 company.  In addition to a refreshing, profit driven business model, Merlin
 has assembled a world-class management team and board of directors. We expect
 Merlin to grow rapidly and prosper."
     Merlin (http://www.merlintechnologie.com) is an early stage pharmaceutical
 company based in Boston. The Company is focused on the detection and treatment
 of stealth infections, and the chronic diseases that they trigger.  Merlin
 expects to enter clinical trials this year with its first antibiotic new
 chemical entity.
     The Vanderbilt University Chancellor's Fund is based in Nashville.  The
 Fund invests in early and seed stage opportunities in biotechnology,
 information systems and other building blocks of the new economy.
 
 

SOURCE Merlin Technologies, Inc.
    BOSTON, April 18 /PRNewswire/ -- Vanderbilt's Chancellor's Investment Fund
 (Nashville) increased Vanderbilt's equity position in Merlin Technologies,
 Inc. (Boston), an early stage pharmaceutical company, through an investment
 package totaling more than one million dollars.  G. Mick Stadler, Managing
 Director of the Vanderbilt Fund, joined Merlin's prestigious Board of
 Directors. Merlin's Directors include Walter Gilbert, PhD, Nobel laureate and
 former founding CEO of Biogen, Barry Eisenstein, former Lilly executive and
 current VP of Science and Technology at the Beth Israel Deaconess Medical
 Center, and Raymond Baddour, PhD, former chemical engineering chair at MIT and
 co-founder and former director of Amgen.
     Merlin also received exclusive worldwide licensure of Vanderbilt
 intellectual property covering the diagnosis and treatment of certain
 bacterial stealth infections.  Stealth infections, especially persistent
 infections by Chlamydia pneumoniae, have been linked to heart disease,
 multiple sclerosis and many other deadly ailments. Vanderbilt researchers
 Charles W. Stratton, MD and William Mitchell, MD, PhD, and Boston biotech
 entrepreneur, Gary Magnant, co-founded Merlin in 1996.
     Merlin's CEO, Chalom Sayada, MD, PhD called the deal "a key milestone for
 the Company. The addition of Vanderbilt's intellectual property to our
 portfolio gives Merlin the most comprehensive pending patent coverage of its
 kind in the world.  The detection and treatment of Chlamydia pneumoniae and
 the chronic diseases induced by this organism are broadly covered, and will
 enable strong strategic partnerships with large pharmaceutical companies."
     Mick Stadler concurs: "We are pleased to back this exciting early stage
 company.  In addition to a refreshing, profit driven business model, Merlin
 has assembled a world-class management team and board of directors. We expect
 Merlin to grow rapidly and prosper."
     Merlin (http://www.merlintechnologie.com) is an early stage pharmaceutical
 company based in Boston. The Company is focused on the detection and treatment
 of stealth infections, and the chronic diseases that they trigger.  Merlin
 expects to enter clinical trials this year with its first antibiotic new
 chemical entity.
     The Vanderbilt University Chancellor's Fund is based in Nashville.  The
 Fund invests in early and seed stage opportunities in biotechnology,
 information systems and other building blocks of the new economy.
 
 SOURCE  Merlin Technologies, Inc.